For researchers working with reconstituted retatrutide , the math requires careful attention
Cosentino F, Grant PJ, Aboyans V et al (2020) 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Liraglutide (Saxenda): What It Is: GLP-1 receptor agonist (same class as semaglutide) Older, less effective version Daily injection required Effectiveness: Average Weight Loss: 5-8% of body weight SCALE Trial: 8% loss vs 2.6% placebo Significantly less effective than semaglutide (daily) or tirzepatide Why Less Effective: Shorter half-life requires daily dosing Less consistent drug levels Lower peak concentrations Side Effects: Similar to semaglutide (nausea, diarrhea, constipation) Same GLP-1 class warnings Cost: $1,400/month More expensive than newer, more effective options Who Should Consider: Almost no one Semaglutide and tirzepatide have largely replaced liraglutide Rarely prescribed for weight loss anymore Comparison Table: All FDA-Approved Weight Loss Medications: Bottom Line on Non-GLP-1 Options: For most patients seeking effective weight loss: Best Results: Tirzepatide or semaglutide If GLP-1s Contraindicated: Phentermine-topiramate Avoid: Orlistat, naltrexone-bupropion (poor effectiveness) Short-term Only: Phentermine The GLP-1 revolution has made older medications largely obsolete for patients who can tolerate them

The move comes nearly eighteen months after Oprah Winfrey, a Weight Watchers investor who served as the celebrity face and body of the diet company, admitted that she had started taking weight loss drugs like Novo Nordisks Ozempic and Wegovy
Retatrutide: Important Things to Keep in Mind 1
Under the revised criteria, Michigan Medicaid will continue coverage for GLP-1 weight-loss medications for individuals who fall into one of two categories: 1